Prolonged sleep restriction induces changes in pathways involved in cholesterol metabolism and inflammatory responses

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Aho, Vilma ^a   Ollila, Hanna M ^a,b,c,d   Kronholm, Erkki ^b   Bondia Pons, Isabel ^e,f   Soininen, Pasi ^g,h   Kangas, Antti J ^g   Hilvo, Mika ^e   Seppälä, Ilkka ⁱ   Kettunen, Johannes ^b,g,h   Oikonen, Mervi ^j   Raitoharju, Emma ⁱ   Hyötyläinen, Tuulia ^e,f   Kähönen, Mika ⁱ   Viikari, Jorma S A ^k   Härmä, Mikko ^l   Sallinen, Mikael ^l,m   Olkkonen, Vesa M ^n,o   Alenius, Harri ^l   Jauhiainen, Matti ^b   Paunio, Tiina ^b,c   Lehtimäki, Terho ⁱ   Salomaa, Veikko ^b   Orešič, Matej ^e,f   Raitakari, Olli T ^j,k   Ala Korpela, Mika ^g,h,p,q   Porkka Heiskanen, Tarja ^a   more..

^a UNIVERSITY OF HELSINKI   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d STANFORD UNIVERSITY   (United States)

^e VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^f STENO DIABETES CENTER   (Denmark)

^g UNIVERSITY OF OULU   (Finland)

^h UNIVERSITY OF EASTERN FINLAND   (Finland)

ⁱ TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^j UNIVERSITY OF TURKU   (Finland)

^k TURKU UNIVERSITY HOSPITAL   (Finland)

^l FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^m UNIVERSITY OF JYVÄSKYLÄ   (Finland)

ⁿ MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

^o UNIVERSITY OF HELSINKI   (Finland)

^p OULU UNIVERSITY HOSPITAL   (Finland)

^q UNIVERSITY OF BRISTOL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL;

ADULT; AGED; BLOOD ANALYSIS; COMPLICATION; FEMALE; FINLAND; GENE EXPRESSION PROFILING; HUMAN; INFLAMMATION; MALE; METABOLIC DISORDER; METABOLISM; METABOLOME; MIDDLE AGED; PATHOPHYSIOLOGY; SLEEP DEPRIVATION;

ADULT; AGED; BLOOD CHEMICAL ANALYSIS; CHOLESTEROL; FEMALE; FINLAND; GENE EXPRESSION PROFILING; HUMANS; INFLAMMATION; MALE; METABOLIC DISEASES; METABOLOME; MIDDLE AGED; SLEEP DEPRIVATION;

EID: 84964253389     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24828     Document Type: Article

References (93)

1. Grandner, M. A., Jackson, N. J., Pak, V. M. & Gehrman, P. R. Sleep disturbance is associated with cardiovascular and metabolic disorders. J. Sleep Res. 21, 427-433 (2012).
2. Kronholm, E., Laatikainen, T., Peltonen, M., Sippola, R. & Partonen, T. Self-reported sleep duration, all-cause mortality, cardiovascular mortality and morbidity in Finland. Sleep Med. 12, 215-221 (2011).
3. Cappuccio, F. P., D'Elia, L., Strazzullo, P. & Miller, M. A. Quantity and quality of sleep and incidence of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care 33, 414-420 (2010).
4. Spiegel, K., Tasali, E., Leproult, R. & Van Cauter, E. Effects of poor and short sleep on glucose metabolism and obesity risk. Nat. Rev. Endocrinol. 5, 253-261 (2009).
5. Aho, V. et al. Partial sleep restriction activates immune response-related gene expression pathways: experimental and epidemiological studies in humans. Plos One 8, e77184 (2013).
6. Meier-Ewert, H. K. et al. Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J. Am. Coll. Cardiol. 43, 678-683 (2004).
7. van Leeuwen, W. M. et al. Sleep restriction increases the risk of developing cardiovascular diseases by augmenting proinflammatory responses through IL-17 and CRP. Plos One 4, e4589 (2009).
8. Moller-Levet, C. S. et al. Effects of insufficient sleep on circadian rhythmicity and expression amplitude of the human blood transcriptome. Proc. Natl. Acad. Sci. USA 110, E1132-41 (2013).
9. Spiegel, K., Knutson, K., Leproult, R., Tasali, E. & Van Cauter, E. Sleep loss: a novel risk factor for insulin resistance and Type 2 diabetes. J. Appl. Physiol. 99, 2008-2019 (2005).
10. Donga, E. et al. A single night of partial sleep deprivation induces insulin resistance in multiple metabolic pathways in healthy subjects. J. Clin. Endocrinol. Metab. 95, 2963-2968 (2010).
11. Van Cauter, E., Spiegel, K., Tasali, E. & Leproult, R. Metabolic consequences of sleep and sleep loss. Sleep Med. 9, Suppl 1, S23-8 (2008).
12. Reynolds, A. C. et al. Impact of five nights of sleep restriction on glucose metabolism, leptin and testosterone in young adult men. Plos One 7, e41218 (2012).
13. Boudjeltia, K. Z. et al. Temporal dissociation between myeloperoxidase (MPO)-modified LDL and MPO elevations during chronic sleep restriction and recovery in healthy young men. Plos One 6, e28230 (2011).
14. O'Keeffe, M., Roberts, A. L., Kelleman, M., Roychoudhury, A. & St-Onge, M. P. No effects of short-term sleep restriction, in a controlled feeding setting, on lipid profiles in normal-weight adults. J. Sleep Res. 22, 717-720 (2013).
15. Tall, A. R. An overview of reverse cholesterol transport. Eur. Heart J. 19, Suppl A, A31-5 (1998).
16. Arsenault, B. J. et al. HDL particle size and the risk of coronary heart disease in apparently healthy men and women: the EPICNorfolk prospective population study. Atherosclerosis 206, 276-281 (2009).
17. Pirillo, A., Norata, G. D. & Catapano, A. L. High-density lipoprotein subfractions-what the clinicians need to know. Cardiology 124, 116-125 (2013).
18. Kasukawa, T. et al. Human blood metabolite timetable indicates internal body time. Proc. Natl. Acad. Sci. USA 109, 15036-15041 (2012).
19. Dallmann, R., Viola, A. U., Tarokh, L., Cajochen, C. & Brown, S. A. The human circadian metabolome. Proc. Natl. Acad. Sci. USA 109, 2625-2629 (2012).
20. Ang, J. E. et al. Identification of human plasma metabolites exhibiting time-of-day variation using an untargeted liquid chromatography-mass spectrometry metabolomic approach. Chronobiol. Int. 29, 868-881 (2012).
21. Chua, E. C. et al. Extensive diversity in circadian regulation of plasma lipids and evidence for different circadian metabolic phenotypes in humans. Proc. Natl. Acad. Sci. USA 110, 14468-14473 (2013).
22. Davies, S. K. et al. Effect of sleep deprivation on the human metabolome. Proc. Natl. Acad. Sci. USA 111, 10761-6 (2014).
23. Weljie, A. M. et al. Oxalic acid and diacylglycerol 36:3 are cross-species markers of sleep debt. Proc. Natl. Acad. Sci. USA 112, 2569-2574 (2015).
24. Giskeødegård, G. F., Davies, S. K., Revell, V. L., Keun, H. & Skene, D. J. Diurnal rhythms in the human urine metabolome during sleep and total sleep deprivation. Sci. Rep. 5, 14843 (2015).
25. Inouye, M. et al. Metabonomic, transcriptomic, and genomic variation of a population cohort. Mol. Syst. Biol. 6, 441 (2010).
26. Raitakari, O. T. et al. Cohort Profile: The Cardiovascular Risk in Young Finns Study. Int. J. Epidemiol. 37, 1220-1226 (2008).
27. Leger, D. et al. Short sleep in young adults: Insomnia or sleep debt? Prevalence and clinical description of short sleep in a representative sample of 1004 young adults from France. Sleep Med. 12, 454-462 (2011).
28. Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57 (2009).
29. Soininen, P., Kangas, A. J., Würtz, P., Suna, M. & Ala-Korpela, M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circ Cardiovasc Genet. 8, 192-206 (2015).
30. Joseph, S. B., Castrillo, A., Laffitte, B. A., Mangelsdorf, D. J. & Tontonoz, P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 9, 213-219 (2003).
31. Tall, A. R. & Yvan-Charvet, L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 15, 104-116 (2015).
32. Lee, S. D. & Tontonoz, P. Liver X receptors at the intersection of lipid metabolism and atherogenesis. Atherosclerosis 242, 29-36 (2015).
33. Castrillo, A. et al. Crosstalk between LXR and Toll-like Receptor Signaling Mediates Bacterial and Viral Antagonism of Cholesterol Metabolism. Mol. Cell 12, 805-816 (2003).
34. Choi, J. Y. et al. Mer signaling increases the abundance of the transcription factor LXR to promote the resolution of acute sterile inflammation. Sci. Signal. 8, ra21 (2015).
35. Dushkin, M. I., Khoshchenko, O. M., Chasovsky, M. A. & Pivovarova, E. N. The content of PPAR, LXR, and RXR and the PPAR DNA-binding activity in macrophages over the course of inflammation in mice. Bull. Exp. Biol. Med. 147, 345-348 (2009).
36. Kim, M. S. et al. Tumor necrosis factor and interleukin 1 decrease RXRα , PPARα , PPARγ, LXRα , and the coactivators SRC-1, PGC- 1α , and PGC-1β in liver cells. Metab. Clin. Exp. 56, 267-279 (2007).
37. Krueger, J. M., Obal, F. J., Fang, J., Kubota, T. & Taishi, P. The role of cytokines in physiological sleep regulation. Ann. N. Y. Acad. Sci. 933, 211-221 (2001).
38. Schafer, J. & Strimmer, K. An empirical Bayes approach to inferring large-scale gene association networks. Bioinformatics 21, 754-764 (2005).
39. Venteclef, N., Jakobsson, T., Steffensen, K. R. & Treuter, E. Metabolic nuclear receptor signaling and the inflammatory acute phase response. Trends Endocrinol. Metab. 22, 333-343 (2011).
40. Rosenson, R. S. et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat. Rev. Cardiol. 13, 48-60 (2016).
41. Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B. & Dawber, T. R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 62, 707-714 (1977).
42. Tariq, S. M., Sidhu, M. S., Toth, P. P. & Boden, W. E. HDL hypothesis: where do we stand now? Curr. Atheroscler. Rep. 16, 398 (2014).
43. Rosenson, R. S. et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 125, 1905-1919 (2012).
44. Haas, M. J. & Mooradian, A. D. Inflammation, high-density lipoprotein and cardiovascular dysfunction. Curr. Opin. Infect. Dis. 24, 265-272 (2011).
45. Karlsson, H., Kontush, A. & James, R. W. Functionality of HDL: antioxidation and detoxifying effects. Handb. Exp. Pharmacol. 224, 207-228 (2015).
46. Riwanto, M. et al. Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation 127, 891-904 (2013).
47. Rayner, K. J. & Moore, K. J. MicroRNA control of high-density lipoprotein metabolism and function. Circ. Res. 114, 183-192 (2014).
48. Hohagen, F. et al. Prevalence and treatment of insomnia in general practice. A longitudinal study. Eur. Arch. Psychiatry Clin. Neurosci. 242, 329-336 (1993).
49. Henderson, S. et al. Insomnia in the elderly: its prevalence and correlates in the general population. Med. J. Aust. 162, 22-24 (1995).
50. Bixler, E. O., Vgontzas, A. N., Lin, H. M., Vela-Bueno, A. & Kales, A. Insomnia in central Pennsylvania. J. Psychosom. Res. 53, 589-592 (2002).
51. Kim, K., Uchiyama, M., Okawa, M., Liu, X. & Ogihara, R. An epidemiological study of insomnia among the Japanese general population. Sleep 23, 41-47 (2000).
52. Jones, S., Pfister-Genskow, M., Benca, R. M. & Cirelli, C. Molecular correlates of sleep and wakefulness in the brain of the whitecrowned sparrow. J. Neurochem. 105, 46-62 (2008).
53. Cirelli, C., Gutierrez, C. M. & Tononi, G. Extensive and divergent effects of sleep and wakefulness on brain gene expression. Neuron 41, 35-43 (2004).
54. Yvan-Charvet, L. et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J. Clin. Invest. 117, 3900-3908 (2007).
55. Oram, J. F. & Vaughan, A. M. ATP-Binding cassette cholesterol transporters and cardiovascular disease. Circ. Res. 99, 1031-1043 (2006).
56. Liu, M., Chung, S., Shelness, G. S. & Parks, J. S. Hepatic ABCA1 and VLDL triglyceride production. Biochim. Biophys. Acta 1821, 770-777 (2012).
57. Azzam, K. M. & Fessler, M. B. Crosstalk between reverse cholesterol transport and innate immunity. Trends Endocrinol. Metab. 23, 169-178 (2012).
58. Fielding, C. J. & Fielding, P. E. Caveolae and intracellular trafficking of cholesterol. Adv. Drug Deliv. Rev. 49, 251-264 (2001).
59. Chidlow, J. H., Jr & Sessa, W. C. Caveolae, caveolins, and cavins: complex control of cellular signalling and inflammation. Cardiovasc. Res. 86, 219-225 (2010).
60. Mukhamedova, N. et al. Enhancing apolipoprotein A-I-dependent cholesterol efflux elevates cholesterol export from macrophages in vivo. J. Lipid Res. 49, 2312-2322 (2008).
61. Gu, H. M., Wang, F. Q. & Zhang, D. W. Caveolin-1 interacts with ATP binding cassette transporter G1 (ABCG1) and regulates ABCG1-mediated cholesterol efflux. Biochim. Biophys. Acta 1841, 847-858 (2014).
62. Wang, L. et al. Caveolin-1 does not affect SR-BI-mediated cholesterol efflux or selective uptake of cholesteryl ester in two cell lines. J. Lipid Res. 44, 807-815 (2003).
63. Terasaka, N. et al. ATP-binding cassette transporter G1 and high-density lipoprotein promote endothelial NO synthesis through a decrease in the interaction of caveolin-1 and endothelial NO synthase. Arterioscler. Thromb. Vasc. Biol. 30, 2219-2225 (2010).
64. Faraut, B., Boudjeltia, K. Z., Vanhamme, L. & Kerkhofs, M. Immune, inflammatory and cardiovascular consequences of sleep restriction and recovery. Sleep Med. Rev. 16, 137-149 (2012).
65. Mullington, J. M., Simpson, N. S., Meier-Ewert, H. K. & Haack, M. Sleep loss and inflammation. Best Pract. Res. Clin. Endocrinol. Metab. 24, 775-784 (2010).
66. Carpentier, Y. A. & Scruel, O. Changes in the concentration and composition of plasma lipoproteins during the acute phase response. Curr. Opin. Clin. Nutr. Metab. Care 5, 153-158 (2002).
67. Khovidhunkit, W. et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 45, 1169-1196 (2004).
68. Hotamisligil, G. S. Inflammation and metabolic disorders. Nature 444, 860-867 (2006).
69. Grandner, M. A., Patel, N. P., Gehrman, P. R., Perlis, M. L. & Pack, A. I. Problems associated with short sleep: bridging the gap between laboratory and epidemiological studies. Sleep Med. Rev. 14, 239-247 (2010).
70. Altman, N. G. et al. Sleep duration versus sleep insufficiency as predictors of cardiometabolic health outcomes. Sleep Med. 13, 1261-1270 (2012).
71. Abe, T., Komada, Y. & Inoue, Y. Short sleep duration, snoring and subjective sleep insufficiency are independent factors associated with both falling asleep and feeling sleepiness while driving. Intern. Med. 51, 3253-3260 (2012).
72. Bass, J. & Takahashi, J. S. Circadian integration of metabolism and energetics. Science 330, 1349-1354 (2010).
73. Machado, R. M. & Koike, M. K. Circadian rhythm, sleep pattern, and metabolic consequences: an overview on cardiovascular risk factors. Horm. Mol. Biol. Clin. Investig. 18, 47-52 (2014).
74. Banks, S., Van Dongen, H. P., Maislin, G. & Dinges, D. F. Neurobehavioral dynamics following chronic sleep restriction: doseresponse effects of one night for recovery. Sleep 33, 1013-1026 (2010).
75. van Leeuwen, W. M. et al. Prolonged sleep restriction affects glucose metabolism in healthy young men. Int. J. Endocrinol. 2010, 108641 (2010).
76. Haavisto, M. L. et al. Sleep restriction for the duration of a work week impairs multitasking performance. J. Sleep Res. 19, 444-454 (2010).
77. Rechtschaffen, A. & Kales, A. In A manual of standardized terminology: techniques and scoring system for sleep stages of human subjects (UCLA Brain Information Service, Los Angeles, 1968).
78. National Nutrition Council of Finland. Finnish nutrition recommendations - balancing energy intake and energy expenditure (2005). Available (in Finnish) at: http://www.ravitsemusneuvottelukunta.fi/attachments/vrn/ravitsemussuositus2005.fin.pdf (Accessed: 23rd March 2016).
79. Markwald, R. R. et al. Impact of insufficient sleep on total daily energy expenditure, food intake, and weight gain. Proc. Natl. Acad. Sci. USA 110, 5695-5700 (2013).
80. Inouye, M. et al. An immune response network associated with blood lipid levels. Plos Genet. 6, e1001113 (2010).
81. Niiranen, T. J., Kronholm, E., Rissanen, H., Partinen, M. & Jula, A. M. Self-reported obstructive sleep apnea, simple snoring, and various markers of sleep-disordered breathing as predictors of cardiovascular risk. Sleep Breath doi: 10.1007/s11325-015-1253-4 (2015).
82. Raitoharju, E. et al. Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways underlying metabolic syndrome: the cardiovascular risk in Young Finns Study. Mol. Cell. Endocrinol. 391, 41-49 (2014).
83. Wurtz, P. et al. Metabolic signatures of insulin resistance in 7, 098 young adults. Diabetes 61, 1372-1380 (2012).
84. Kujala, U. M. et al. Long-term leisure-time physical activity and serum metabolome. Circulation 127, 340-348 (2013).
85. Kettunen, J. et al. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat. Genet. 44, 269-276 (2012).
86. Soininen, P. et al. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst 134, 1781-1785 (2009).
87. Nygren, H., Seppanen-Laakso, T., Castillo, S., Hyotylainen, T. & Oresic, M. Liquid chromatography-mass spectrometry (LC-MS)- based lipidomics for studies of body fluids and tissues. Methods Mol. Biol. 708, 247-257 (2011).
88. Pluskal, T., Castillo, S., Villar-Briones, A. & Oresic, M. MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinformatics 11, 395 (2010).
89. Groener, J. E., Pelton, R. W. & Kostner, G. M. Improved estimation of cholesteryl ester transfer/exchange activity in serum or plasma. Clin. Chem. 32, 283-286 (1986).
90. Jauhiainen, M. et al. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J. Biol. Chem. 268, 4032-4036 (1993).
91. Jauhiainen, M. & Dolphin, P. J. Human plasma lecithin-cholesterol acyltransferase. An elucidation of the catalytic mechanism. J. Biol. Chem. 261, 7032-7043 (1986).
92. Kleemola, P. et al. Dietary determinants of serum paraoxonase activity in healthy humans. Atherosclerosis 160, 425-432 (2002).
93. Brohee, S., Faust, K., Lima-Mendez, G., Vanderstocken, G. & van Helden, J. Network Analysis Tools: from biological networks to clusters and pathways. Nat. Protoc. 3, 1616-1629 (2008).